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Abstract. The paper presents the findings of our own study on the changes of the systemic 
inflammation in patients with type 2 diabetes mellitus (DM2) and ischemic heart disease 
(IHD) during the combination treatment with metformin and pioglitazone. 95 patients with 
IHD concomitant with DM2 have been treated. Patients, enrolled into study, have been 
randomized into 2 groups: the comparison group (n=37) treated with metformin and 
sulphonylureas, and the study group (n=58) treated with metformin and pioglitazone. The 
proposed course of therapy lasted 6 months. Before, after 3 and 6 months of treatment the 
control over the state of inflammatory responses was made and C-reactive protein, tumor 
necrosis factor-alpha, Interleukin-6 was assessed. The resulting data confirmed a statistically 
significant reduction under the effect of the combined treatment with the proposed 
combination of marker drugs and the degree of chronic systemic inflammation that is specific 
for IHD and DM2, which has a positive impact on the development and progress of IHD in 
DM2 patients, is well tolerated and can be considered as a pathogenic factor in the therapy of 
the presented comorbid nosologies.  
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ХРОНІЧНЕ СИСТЕМНЕ ЗАПАЛЕННЯ В ПАТОГЕНЕЗІ КОМОРБІДНОЇ 
ПАТОЛОГІЇ ТА ЙОГО КОРЕКЦІЯ 
Шаєнко З.О., Винник Н.І., Бобирьова Л.Є., Попруга А.О. 
Резюме. У статті представлені результати власних досліджень про динаміку зміни 
системного запалення у хворих на цукровий діабет 2 типу (ЦД) та ішемічну хворобу 
серця (ІХС) при комбінованому лікуванні метформіном та піоглітазоном. Проліковано 
95 хворих з ІХС у поєднанні з ЦД 2 типу. Пацієнти, включені у дослідження, були 
рандомізовані на 2 групи: група порівняння (37 чоловік), які отримували метформін та 
препарати сульфонілсечовини та група спостереження (58 пацієнтів), яким до 
метформіну в терапію був включений піоглітазон. Запропонований курс терапії тривав 
6 місяців. Через 3 та 6 місяців лікування проводили контроль стану запальної відповіді 
– визначали С-реактивний білок, фактор некрозу пухлин-альфа, інтерлейкін 6. 
Отримані нами дані підтверджують статистично значиме зниження маркерів та рівня 
хронічного системного запалення, яке характерне для ІХС та ЦД 2 типу, під дією 
комбінованого лікування, що має позитивний вплив на розвиток та перебіг ІХС у 
хворих з ЦД 2 типу, добре переноситься пацієнтами та може розглядатися як 
патогенетичний чинник в терапії даних коморбідних нозологій. 
Ключові слова: цукровий діабет, ішемічна хвороба серця, хронічне системне 
запалення. 
 
INTRODUCRION  
It has been recognized that chronic retarded inflammatory process (CSI) and CSI-
induced insulin resistance (IR) underlies the  pathogenesis of multiple chronic diseases, in 
particular, type 2 diabetes mellitus, atherosclerosis and its complications in the form of 
coronary heart disease [1,2].  The CSI is activated by various stressors, namely, infections, 
intoxications, injuries, oxidative stress, metabolic disorders that lead to the disorder of the 
immune system, primarily its monocytic-macrophage link, accompanied by hyperproduction 
of proinflammatory cytokines [4,6,7]. Nuclear transcription factors of both proinflammatory 
(for example, NFkB) and inflammatory (for example, PPARγ -activated receptors) nature are 
crucial in these processes [3,5,10]. 
Recently, the pharmacological therapy has been tending to use the combination of blood 
glucose-lowering drugs with different mechanism of action that affect the IR and CSI [4, 7, 
8,14]. Pioglitazone (PG) and metformin (MF) has an effect on the leading links of DM2 
pathogenesis, acting through different mechanisms and different affinity to the target tissues. 
MF acts mainly in the liver, inhibiting gluconeogenesis and reducing the activity of the 
nuclear proinflammatory transcription factor (NFkB) [5,9,13].  The effect of PG is focused in 
the adipose tissue, muscle and macrophages and overcomes the insulin resistance by nuclear 
transcription factors-receptors which activate proliferation bythe peroxisome-gamma 
(PPARγ) [3,10,11, 12]. This combination reduces the risk of weight gain, which is typical for 
monotherapy by glitazones, is well tolerated by patients and, as current publications report, 
effectively reduces all macrovascular diabetes complications [4, 8,14].  
Many publications report on investigation of the effect of glitazones and biguanides, 
given separately, on glycemic control in patients with type 2 diabetes mellitus [9,11,12,13]; 
however, their combination, used in treatment of patients with DM2 concomitant with IHD is 
still not completely studied.  
PURPOSE 
The aim of the paper is to define the dynamics of the systemic inflammation in 
patients with type 2 diabetes mellitus and ischemic heart disease in combination treatment 
with metformin and pioglitazone.  
MATERIAL AND METHODS. The study has been carried out at the Research 
Institute for Genetic and Immunological Grounds of Pathology and Pharmacogenetics of the 
Higher State Educational Establishment of Ukraine “Ukrainian Medical Stomatological 
Academy” and at the Endocrynology Unit of the O.T. Bogaievskii Kremenchuk First 
Municipal Hospital. 95 patients (39 men and 56 women) with ischemic heart disease and type 
2 diabetes mellitus and have been treated. The mean age of the patients was 59.40 ± 8.01 
years. The mean duration of DM2 was 5,3±07. Prior to the involvement into study the patients 
received metformin; the mean level of the monotherapy-related НвА1was 8,90±0,76%. The 
patients, enrolled into study, have been randomized into 2 groups: the comparison group 
(n=37), treated with metformin (Siofor®, Berlin-Chemie Menarini) at a dose of 1700-2550 
mg/day and sulfonylureas at a daily dose of 30 to 60 mg according to the body weight and 
glycemia index; the study group (n=58), who received 30 mg/day pioglitazone (Pioglar®, 
Ranbaxy Laboratories Ltd, Ind. Area ), an insulin sensitizer (a thiazolidinedione), in 
association with metformin. The proposed mode of treatment has been patented in Ukraine 
[8]. 
The IHD has been diagnosed in compliance with the WHO’s criteria. DM2 has been 
diagnosed according to the Unified clinical protocol of the primary and secondary medical 
care (approved by the Ministry of Health as of 21.12.2012, No. 1118).  
Once the screening was made, all patients received the standard comprehensive 
medicamentous therapy to achieve stabilization of the IHD indices: 20 mg isosorbide dinitrate 
twice a day, 75 mg/day acetylsalicylic acid, 10 mg/day amlodipine, 2,5-5 mg/day bisoprolol, 
10 mg/day atorvastatin. The patients received conventional treatment during a month. 
Additionally, the recommendations on healthier nutrition and lifestyle have been given to all 
patients.  
Inclusion criteria for clinical study are: men and women aged 45 to 65 years, with 
confirmed diagnosis of IHD, subcompensated type 2 diabetes mellitus, class I-III obesity and 
hypertension.  
The proposed course of treatment [8] lasted for 6 months. Before, after 3 and 6 months 
of treatment the control over the state of inflammatory response was made. The level of C-
reactive protein was assessed in both groups, whereas the tumor necrosis factor-alpha (TNF-
α) and interleukin 6 (IL-6) was assessed in 36 patients of the study group, using the test-
system set (ZAO „Vektor-Best”, Russia). The statistical analysis of the results was made by 
the BioStat software (Analyst Soft Inc, ver. 2009 for Windows), using the Mann–Whitney U 
test (for independent samples) and the Wilcoxon test (for dependent samples) and χ2 test. 
The drug tolerance has been evaluated by the incidence of undesirable events and side 
effects. The safety was determined by the incidence of episodes of hypoglycemia, allergic 
reactions, as well as by the results of biochemical blood examination, complete blood count 
and urinalysis. 
RESULTS AND DISCUSSION 
The study of the degree of systemic inflammation in the groups of patients has 
established that after 3 months of treatment the level of TNF-α and IL-6 reduced by 29,6% 
and 44,1%, respectively, in patients treated with MF and sulfonylureas as compared with 
56,34% (р=0,027) and 56,4% (р=0,035), respectively, in patients treated with  MF in 
combination with PG. After 6 months of treatment in the comparison group the level of TNF-
α and IL-6 reduced by 54,4% and 61%, respectively, whereas in the study group it reduced by 
76,8% (р<0,001) and  68,1% (р=0,013), respectively (Table 1).  
Table 1 
Indices of systemic inflammation (study group) in patients with IHD and DM2 before 
and after treatment (М±σ) 
 
Index, 
units of 
measure 
Study group (n=36) 
р 
Before treatment  
After 3 months of 
treatment  
After 6 months of 
treatment  
TNF-α, 
pg/ml 
 
6,3±1,91 2,05±1,53 1,17±0,68 < 0,001 
IL-6, 
pg/ml 
5,11±2,38 2,67±1,67 1,31±0,67 < 0,001 
  
We have established that index of blood plasma C-reactive protein before treatment 
was positive in both groups of patients (Table 2). After 3 months of treatment the C-reactive 
protein was detected in 50 (86,2%) patients treated with MF in combination with PG and in 
34 (91,9%) of patients who received MF and sulfonylureas (р=0,007). After 6 months of 
treatment it was found in 43 (74%) patients of study group and in 33 (89,2%) patients of the 
comparison group (р=0,033) (Table 2). 
Table 2 
The level of C-reactive protein in patients with IHD and DM2 before and after 
treatment (М±σ) 
Clinical study groups  
Before treatment  After 6 months of treatment  
Study group 
(n=58) 
Comparison group  
(n=37) 
Study group  
(n=58) 
Comparison group  
(n=37) 
+ - + - + - + - 
58 
(100%) 
- 
37 
100% 
- 
43 
(74,13%) 
15 
(25,87%) 
33 
(89,2%) 
4 
(10,8%) 
р=1,0 р=0,033 
 
Consequently, the MF/PG combination treatment of patients with DMA concomitant 
with IHD leads to a statistically significant reduction of the TNF-α, IL-6 and C-reactive 
protein compared with MF/sulfonylureas therapy, indicating a powerful anti-inflammatory 
action of their combined use and has a positive impact on the IHD progress in patients with 
DM2.  
No negative interaction of MF and PG with antianginals has been recorded.  Side effects 
were observed in 2 patients (3.63%), not requiring drug discontinuation. No case of the 
marked, clinically manifested edemas has been recorded. The complete blood count and 
urinalysis results showed no negative dynamics. Biochemical indices of the liver and kidney 
functioning were within the normal range. No cases of hypoglycemic reactions, drug 
withdrawal, or discharge of patients from the clinical study due to adverse or allergic 
reactions to the therapy have been reordered during observation.  
Noteworthy, even patients’ keeping to the diet and healthy life-style recommendations, 
as well as comprehensive therapy of IHD with statin add-on therapy leads to a significant 
reduction of the CSI markers, and pioglitazone in association with metformin provides with 
additional anti-inflammatory effect.  
The study of N.I.Vynnyk [11, 12] has shown that in IHD patients with the events of 
metabolic syndrome 30 mg pioglitazone during 6 months significantly reduced the degree of 
systemic inflammation, namely, the level of ceruloplasmin (by 1,24 times, р <0,001), C-
reactive protein (by 2,75 times, р <0,001) and TNF-α (by 2,23 times, р <0,01). The 
observation showed that in the comparison group the level of ceruloplasmin was tending to 
increase (р<0,05). No significant changes in TNF-α  level was observed, and the level of 
hypersensitized C-reactive protein reduced by 2,5 times (р <0,001). The author indicates that 
comparison between the groups shows that within 12 months the significant difference in the 
level of ceruloplasmin (р<0,01) and TNF-α (р<0,01) was preserved. In the group of patients 
who received PG these indices was lower. 
A.V. Lavrenko [13] has reported about the significant decline of inflammation indices 
in patients with IHD and DM2 in the short-term (1 month) therapy with MF at a dose of 1 
g/day.  The level of the IL-1, IL-6 and TNF-α reduced by 51%, 53% and 43%, respectively.  
The patients with metabolic syndrome without DM2 showed significant reduce in these 
indices within 30-40%, except for the TNF-α level that remain without changes. This 
indicates the marked anti-inflammatory effect of MF in both of DM2 individuals and patients 
with metabolic syndrome without DM2.  
The comparison of the resulting data obtained by these authors of the effect of the 
separate use of pioglitazone and metformin on the indicators of inflammation generally 
coincides with the data of our study. However, it should be noted that quantitatively, 
combination therapy is much more effective. In this way, pioglitazone reduces the level of 
TNF-α by 2.23 times, and metformin by 43%, whereas its combination reduces TNF-α by 5 
times. The above data indicate a high anti-inflammatory activity of both MF and PG, and 
especially their combination, in patients with MD2 and IHD.  
CONCLUSIONS 
1. The combination of metformin and pioglitazone in the comprehensive treatment of 
patients with DM2 and IHD leads to statistically significant improvement of the 
indices of systemic inflammation, i.e., the reduce in level of TNF-α, IL-6 and C-
reactive protein by 81,4%,74,4% and 25,87%, respectively.  
2. The metformin and pioglitazone combination therapy is well tolerated by patients, 
improving the quality of life. 
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